Investor Relations represents MorphoSys and its equity story to the financial market and supports the Company's overall strategic communication. Through active and transparent investor relations work, the aim is to enable investors to make an informed decision of the Company.
Publication of the Year-End Results 2022
Publication of First Quarter Interim Statement 2023
Annual General Meeting 2023
Take a closer look at our Financial Guidance 2023 and the Fundamentals of MorphoSys.
MorphoSys stock information in detail.
Our Understanding of Sustainability
We are conscious of the responsibility we share for present and future generations and see sustainable action as a prerequisite for long-term business success.
You are now leaving the MorphoSys.com website. This link will take you to a different website. You are solely responsible for your interactions with that website.
Do you wish to proceed ?
MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.